GSA Capital Partners LLP Cuts Stock Holdings in Biodesix, Inc. $BDSX

GSA Capital Partners LLP lowered its stake in shares of Biodesix, Inc. (NASDAQ:BDSX) by 94.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 48,342 shares of the company’s stock after selling 883,052 shares during the quarter. GSA Capital Partners LLP’s holdings in Biodesix were worth $365,000 as of its most recent SEC filing.

Separately, XTX Topco Ltd boosted its holdings in Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after acquiring an additional 102,494 shares during the last quarter. Institutional investors own 20.96% of the company’s stock.

Wall Street Analysts Forecast Growth

BDSX has been the subject of several analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 target price on shares of Biodesix in a report on Tuesday, February 17th. Wall Street Zen raised shares of Biodesix from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Finally, William Blair upgraded Biodesix from a “market perform” rating to an “outperform” rating in a research note on Friday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Biodesix presently has an average rating of “Moderate Buy” and an average target price of $32.50.

Insider Activity

In other Biodesix news, Director Jack W. Schuler bought 20,000 shares of the business’s stock in a transaction on Monday, January 26th. The stock was purchased at an average price of $11.80 per share, for a total transaction of $236,000.00. Following the completion of the transaction, the director directly owned 1,563,210 shares of the company’s stock, valued at $18,445,878. This trade represents a 1.30% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Scott Hutton sold 3,559 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $10.08, for a total transaction of $35,874.72. Following the completion of the sale, the chief executive officer directly owned 45,413 shares in the company, valued at approximately $457,763.04. This trade represents a 7.27% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders purchased 182,465 shares of company stock valued at $2,084,616 and sold 10,999 shares valued at $116,095. Company insiders own 30.10% of the company’s stock.

Biodesix Trading Up 10.0%

NASDAQ:BDSX opened at $14.22 on Friday. Biodesix, Inc. has a 12 month low of $3.44 and a 12 month high of $19.13. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. The firm’s 50 day moving average is $9.37 and its 200 day moving average is $8.32. The stock has a market capitalization of $113.19 million, a PE ratio of -2.56 and a beta of 0.67.

Biodesix (NASDAQ:BDSX) last released its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.56. The business had revenue of $28.76 million during the quarter, compared to the consensus estimate of $26.25 million. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%. Sell-side analysts expect that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.